SCA
ARKG icon

Stonebridge Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Stonebridge Capital Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200
Closed -$6.01K – 933
2023
Q1 		$6.01K Sell
200
-100
-33% -$3.1K ﹤0.01% 685
2022
Q4 		$8.47K Hold
300
– – ﹤0.01% 625
2022
Q3 		$10K Sell
300
-410
-58% -$15.1K ﹤0.01% 571
2022
Q2 		$22K Buy
+710
New +$24.8K ﹤0.01% 471

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Stonebridge Capital Advisors's ARKG Position: Q2 2023 in Review

Stonebridge Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2023, closing a stake of 200 shares — an estimated $6.01K sold.

Stonebridge Capital Advisors first reported a position in ARKG in Q2 2022 and held it in 4 quarters. The position peaked at $22K in Q2 2022. 290 funds tracked by Wall St. Rank hold ARKG as of Q2 2023.

  • Stonebridge Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2023 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 200 ARK Genomic Revolution ETF shares in Q2 2023, an estimated $6.01K.
  • Stonebridge Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2022 and held it in 4 quarters.
  • Stonebridge Capital Advisors's ARK Genomic Revolution ETF position peaked at $22K in Q2 2022.
  • 290 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2023, filed 23 Aug 2023.